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Abstract
Background
Most countries have formally adopted the World Health Organization’s 2015 recommenda-
tion of universal HIV treatment (“treat all”). However, there are few rigorous assessments of
the real-world impact of treat all policies on antiretroviral treatment (ART) uptake across dif-
ferent contexts.
Methods and findings
We used longitudinal data for 814,603 patients enrolling in HIV care between 1 January
2004 and 10 July 2018 in 6 countries participating in the global International epidemiology
Databases to Evaluate AIDS (IeDEA) consortium: Burundi (N = 11,176), Kenya (N =
179,941), Malawi (N = 84,558), Rwanda (N = 17,396), Uganda (N = 96,286), and Zambia (N
= 425,246). Using a quasi-experimental regression discontinuity design, we assessed the
change in the proportion initiating ART within 30 days of enrollment in HIV care (rapid ART
initiation) after country-level adoption of the treat all policy. A modified Poisson model was
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used to identify factors associated with failure to initiate ART rapidly under treat all. In each
of the 6 countries, over 60% of included patients were female, and median age at enrollment
ranged from 32 to 36 years. In all countries studied, national adoption of treat all was associ-
ated with large increases in rapid ART initiation. Significant increases in rapid ART initiation
immediately after treat all policy adoption were observed in Rwanda, from 44.4% to 78.9%
of patients (34.5 percentage points [pp], 95% CI 27.2 to 41.7; p < 0.001), Kenya (25.7 pp,
95% CI 21.8 to 29.5; p < 0.001), Burundi (17.7 pp, 95% CI 6.5 to 28.9; p = 0.002), and
Malawi (12.5 pp, 95% CI 7.5 to 17.5; p < 0.001), while no immediate increase was observed
in Zambia (0.4 pp, 95% CI −2.9 to 3.8; p = 0.804) and Uganda (−4.2 pp, 95% CI −9.0 to 0.7;
p = 0.090). The rate of rapid ART initiation accelerated sharply following treat all policy adop-
tion in Malawi, Uganda, and Zambia; slowed in Kenya; and did not change in Rwanda and
Burundi. In post hoc analyses restricted to patients enrolling under treat all, young adults
(16–24 years) and men were at increased risk of not rapidly initiating ART (compared to
older patients and women, respectively). However, rapid ART initiation following enrollment
increased for all groups as more time elapsed since treat all policy adoption. Study limita-
tions include incomplete data on potential ART eligibility criteria, such as clinical status,
pregnancy, and enrollment CD4 count, which precluded the assessment of rapid ART initia-
tion specifically among patients known to be eligible for ART before treat all.
Conclusions
Our analysis indicates that adoption of treat all policies had a strong effect on increasing
rates of rapid ART initiation, and that these increases followed different trajectories across
the 6 countries. Young adults and men still require additional attention to further improve
rapid ART initiation.
Author summary
Why was this study done?
• Since late 2015, the World Health Organization (WHO) has recommended that all peo-
ple living with HIV (PLWH) initiate ART, regardless of disease stage and CD4 cell
count, and as of mid-2018, 84% of low- and middle-income countries had formally
adopted WHO’s recommendation to provide universal treatment to all PLWH.
• While modeling studies and trials have indicated that universal treatment, or “treat all,”
increases rapid ART initiation and viral load suppression among patients, there is little
evidence on the impact of treat all policies on uptake of ART in real-world implementa-
tion settings.
What did the researchers do and find?
• We assessed rapid ART initiation (i.e., ART initiation within 30 days of enrolling into
HIV care) among 814,603 patients before and after national adoption of treat all policies
in 6 countries in sub-Saharan Africa (Burundi, Kenya, Malawi, Rwanda, Uganda, and
Zambia).
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• To compare rapid ART initiation among those enrolling into care just before and just
after national adoption of the treat all policy, we used a regression discontinuity design,
using the date of HIV care enrollment as a continuous eligibility assignment variable.
This design creates a quasi-experimental condition where the only systematic difference
between patients enrolling just before and just after treat all policy adoption is the prob-
ability of treatment eligibility.
• There were large increases in rapid ART initiation after national adoption of treat all,
with 81.6% of patients initiating ART within 30 days of enrollment after the policy adop-
tion, and little difference in rapid ART initiation across patients with different immuno-
deficiency status, as measured by CD4 counts.
• In Burundi, Kenya, Malawi, and Rwanda, there were large and significant increases in
rapid ART initiation immediately following national adoption of treat all, ranging from
12.5- and 17.7-percentage-point increases in rapid ART initiation in Malawi and
Burundi, respectively, to 25.7- and 34.5-percentage-point increases in Kenya and
Rwanda.
• In Uganda and Zambia, there was no significant increase in rapid ART initiation imme-
diately following national adoption of treat all. However, there were significant increases
in the rate of rapid ART initiation in the months following treat all adoption, with each
additional month following the policy adoption being associated with 2.2- and 2.6-per-
centage-point increases in the proportion of patients initiating ART in Uganda and
Zambia, respectively.
• In the period following treat all adoption, men and young adults (aged 16–24 years)
were less likely to rapidly initiate ART than women and older adults, respectively. How-
ever, for all groups, the risk of failing to rapidly initiate ART significantly decreased with
elapsed time after treat all policy adoption.
What do these findings mean?
• Using a regression discontinuity design and real-world service delivery data, primarily
from public-sector health facilities, our findings suggest that national adoption of treat
all policies has led to appreciable increases in rapid ART initiation.
• As more follow-up data become available, future research should assess longer-term
outcomes, such as retention in care, viral suppression, and treatment failure among
patients initiating therapy under treat all.
Introduction
In September 2015, after a series of clinical-stage- and CD4-count-based antiretroviral therapy
(ART) eligibility expansions [1], the World Health Organization (WHO) recommended that
all people living with HIV (PLWH) should start ART regardless of disease stage and at any
CD4 cell count [2]. In 2017, WHO recommended treatment initiation within 7 days of con-
firming HIV diagnosis, including same-day ART initiation when feasible [3]. This recommen-
dation followed from the results of several randomized trials and observational studies
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showing that rapid ART initiation was associated with reduced mortality and morbidity, and
with a greater likelihood of achieving virological suppression and retention in care [4]. If initi-
ated rapidly, universal HIV treatment (also known as “treat all” and “test and start”) is thus an
important strategy for reaching the Joint United Nations Programme on HIV/AIDS
(UNAIDS) 90-90-90 targets.
Implementation of treat all is accelerating, and as of mid-2018, 84% of low- and middle-
income countries had formally adopted the recommendation to provide universal treatment
to PLWH [5]. Given the relatively recent rollout of treat all policies at the country level, how-
ever, there is little evidence to date on the policy’s real-world effect on ART uptake. As the
number of patients on ART grows under treat all policies, it is also critical to examine how the
policy impacts patient groups that have historically lagged behind in HIV care engagement
(i.e., men and young adults). While changes in ART initiation following WHO’s 2009 and
2013 ART eligibility expansion recommendations have been evaluated [6–8], most estimates
of the potential impact of treat all to date come from trials and modeling studies [9–13].
Although most of these research studies have reported favorable outcomes, they may not be
generalizable to other contexts, including settings where health system and other resource con-
straints contribute to delays in policy implementation.
In this study, we used longitudinal patient data from 6 countries participating in the Inter-
national epidemiology Databases to Evaluate AIDS (IeDEA) consortium to describe ART initi-
ation rates under different country-level eligibility guidelines, to assess the impact of treat all
policies on rapid ART initiation, and to identify factors associated with failure to start treat-
ment rapidly under treat all.
Methods
Data sources and management
Patient data. IeDEA (https://www.iedea.org) captures demographic and clinical data on
over 1.7 million patients receiving HIV care in 46 countries across 7 regional cohort collabora-
tions [14]. The data represent a diverse cross-section of PLWH and HIV treatment programs,
the majority of which (87%) are at public-sector health facilities, including both primary (42%)
and secondary/tertiary-level sites (58%) [15]. In this analysis, we used medical records from
patients enrolled in these programs between 1 January 2004 and 10 July 2018 in 6 countries in
3 regional cohorts with post-treat-all data available for analysis (Burundi and Rwanda in Cen-
tral Africa, Kenya and Uganda in East Africa, and Malawi and Zambia in Southern Africa).
Prior to merging and analysis, each region’s data were standardized by regional data managers
in accordance with IeDEA data exchange standards for variable definitions and data
formatting.
ART guidelines. For each country in the analysis, we identified the dates of major ART
eligibility expansions to CD4� 350 cells/μl, CD4� 500 cells/μl, and treat all. We have previ-
ously described our systematic search for current and historical ART eligibility guidelines
based on publicly available policy documents, published literature, and inputs from in-country
experts [6]. If the exact date of ART eligibility expansion was unknown, it was assumed to have
occurred on the first day of the month in which the policy was adopted. In Malawi, the date of
national treat all adoption published in the country’s guidelines was adjusted to 2 months later
to reflect the delays in policy rollout documented by the Ministry of Health [16].
The study utilized de-identified data approved for use by local ethical committees in each of
the IeDEA regions included in the analysis.
Treat all policies and rapid treatment initiation
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Inclusion criteria
Patients had to be at least 16 years old at enrollment and have at least 30 days of possible fol-
low-up between enrollment and database closure. Patients were excluded if they transferred to
an IeDEA site from another clinic or were known not to be ART naïve at enrollment (with
ART defined as any regimen of at least 3 antiretroviral drugs, excluding treatment taken solely
for prevention of mother-to-child transmission). We excluded sites with no patient data avail-
able for the period between care enrollment and ART initiation (i.e., pre-ART data, such as
documented visits and laboratory tests prior to ART initiation), as well as sites that only
reported data for ART initiators (defined as sites where fewer than 2% of patients over the
study period never initiated ART).
Outcome and exposure
The outcome of interest was rapid ART initiation, defined as initiation of treatment within 30
days of enrollment in HIV care (distinct from the 2017 WHO definition of rapid ART initia-
tion as occurring within 7 days of HIV diagnosis) [3]. The exposure was time of enrollment in
HIV care with respect to the calendar date of country-level ART eligibility expansion to treat
all.
Other definitions
To represent pre-treatment HIV disease severity, CD4 count at enrollment was defined as the
CD4 measurement closest to the enrollment date within a ±90-day window, but no later than
1 week after ART initiation.
Study design
Descriptive analyses. The proportion of patients initiating ART rapidly in each of the 4
ART eligibility periods (at CD4� 200 or CD4� 250 cells/μl [period 1]; at CD4� 350 cells/μl
[period 2]; at CD4� 500 cells/μl [period 3]; and treat all [period 4]) was calculated and strati-
fied by country, sex, and age group (dichotomized as 16–24 or�25 years to approximate the
15–24-year age category commonly used by UNAIDS) [17].
Effect of ART eligibility expansion to treat all on rapid ART initiation. A regression
discontinuity design was applied to assess the effect of enrollment in HIV care under treat all
on the proportion of patients initiating ART rapidly. This approach takes advantage of the
local randomness around a cutoff-based, continuous eligibility assignment variable (in this
case, calendar date of HIV care enrollment relative to the date of country-level adoption of
treat all). This local randomness creates a quasi-experimental condition in which there are no
systematic differences between patients enrolling in care on either side of the cutoff threshold
(date of country-level treat all adoption), but patients on one side (those enrolling after treat all
adoption) have a higher probability of initiating treatment than on the other, permitting a
causal interpretation of observed effects [18–20]. Covariate balance tests for patients enrolling
immediately before and after treat all adoption and plots of the assignment variable were com-
pleted to assess the possibility of systematic differences between patients enrolling in HIV care
on either side of the threshold, as well as nonrandom enrollment before or after the treat all
adoption date.
As information about each patient’s ART eligibility at enrollment (e.g., HIV stage, comor-
bidity, pregnancy, and/or key population status) was incomplete, the study is an intent-to-
treat analysis using a “sharp” regression discontinuity design [18,19].
Treat all policies and rapid treatment initiation
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For each of the 6 countries in the analysis, we examined the unadjusted association between
calendar date of enrollment in HIV care and rapid ART initiation. A discontinuity at the
threshold of the date of national treat all policy adoption allowed for different slopes before
and after the cutoff date. To estimate predicted outcomes and risk differences at the treat all
threshold date, the following local linear regression models [21] were used:
E½YijZi� ¼ b0 þ b1 � Zi þ b2 � 1½Zi � 0� þ b3 � Zi � 1½Zi � 0�
where Yi is the patient-level outcome (rapid ART initiation), Zi is the number of days between
a patient’s enrollment date and the national treat all policy introduction date (negative if
patient enrolled before the policy was introduced), and 1[Zi� 0] indicates whether a patient
enrolled after the policy was introduced or not.
Data-driven Imbens–Kalyanaraman bandwidths were applied to minimize the mean
squared error of the difference in predicted values at the threshold date of treat all introduction
[22]. All observations within the bandwidth window were weighted equally (rectangular ker-
nel). Sensitivity analyses were completed using 3 other bandwidth sizes (100, 200, and 300
days). In order to exclude possible threshold effects of prior eligibility expansions, only data
for patients enrolling at least 90 days after the preceding ART eligibility expansion were
included in bandwidth calculations and subsequent treat all regression discontinuity analysis.
Prior to bandwidth calculations, patients enrolling in the 30 days immediately before treat all
adoption were also excluded to ensure that there was no overlap in the outcome estimation
windows (i.e., 30 days following enrollment) of those enrolling before and after the adoption
of treat all. Consequently, to maintain continuity in Zi (with a value of 0 corresponding to the
threshold date of treat all introduction), 30 days were added to remaining enrollment dates
preceding policy introduction. In effect, a patient who enrolled 31 days prior to policy intro-
duction had Zi = −1.
Pooled estimates of the risk difference at the treat all threshold were obtained from meta-
analysis using a DerSimonian and Laird random-effects model, which computed a weighted
average of all 6 countries’ effect estimates based on their standard errors [23].
Trends in rapid ART initiation before and after treat all adoption. To characterize
trends in rapid ART initiation, slopes from linear regression models for the period before
(starting 90 days after ART eligibility expansion to CD4� 500 cells/μl) and after the date of
treat all adoption were compared and expressed as the percentage point (pp) change in rapid
ART initiation per month.
Correlates of failure to initiate ART rapidly under treat all. To identify factors associ-
ated with failure to initiate ART rapidly among patients enrolling in HIV care under treat all, a
multivariable, modified Poisson model with robust error variances was used [24]. A single
model was fitted for all 6 countries, with age group, sex, and time between treat all adoption
and enrollment (categorized into 0 to<3 months, 3 to<6 months, 6 to<12 months, and�12
months) as covariates. To represent other, unobserved confounders and health system fea-
tures, the model also included a variable for country. Enrollment CD4 count was not included
in the model, as it was only available for 37% of the patients.
Descriptive analyses were completed in SAS 9.3 and regression discontinuity analyses in
Stata/IC version 14.2 [25].
The analysis plan was outlined in a May 2018 proposal to the IeDEA Executive Committee
and is documented in S2 Text. The analysis of correlates of failure to initiate ART rapidly
under treat all was not pre-specified.
Treat all policies and rapid treatment initiation
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Results
Sample characteristics
The 6 sub-Saharan African countries in the analysis adopted treat all policies between July and
December 2016. A total of 814,603 patients met the study’s inclusion criteria, ranging from
11,176 in Burundi to 425,246 in Zambia. Overall, median age at enrollment across countries
was 33 years. Over 60% of HIV care enrollees in all 6 countries were women, though the pro-
portion decreased appreciably over time in Kenya and Rwanda (from 67.6% to 59.7% and
from 64.8% to 56.7%, respectively, from period 1 to period 4) (Table 1).
Distribution of baseline characteristics among newly enrolling patients was similar just
before and just after treat all adoption (excluding the 30 days immediately preceding the policy
change) (S1 Table). No major discontinuity in the number of new enrollments around the
date of treat all adoption was observed, consistent with our efforts to exclude sites with no pre-
ART patient data (i.e., treat all did not result in an artificial increase in newly enrolling
patients) (S1 Fig).
Rapid ART initiation under treat all versus in previous ART eligibility
periods (descriptive analysis)
Across the 6 countries, 81.6% of patients enrolling under treat all initiated treatment rapidly
(within 30 days); 59.2% initiated on the day of enrollment in HIV care, and 67.1% within 7
days. Rapid ART initiation under treat all was highest in Malawi (88.9%) and Rwanda (86.9%),
and lowest in Burundi (77.9%) (Table 2).
Overall, rapid ART initiation increased by 25.9 pp under treat all, compared with the
CD4� 500 cells/μl eligibility period (81.6% versus 55.7%). Larger increases in rapid ART initi-
ation under treat all were observed among patients�25 years old than among those aged 16–
24 years (26.5 versus 22.9 pp), whereas following the expansion to ART eligibility at
CD4� 500 cells/μl, larger increases in rapid ART initiation were observed among those aged
16–24 years (23.9 versus 17.2 pp). No appreciable differences by sex were observed. The great-
est increase in the proportion of patients initiating ART rapidly following expansion to treat
all was observed in Rwanda (47.2 pp, from 39.7% to 86.9%) and Kenya (33.8 pp, from 49.3% to
83.1%) (S2 Fig).
Increases in rapid ART initiation were observed at every enrollment CD4 count level after
each ART eligibility expansion. For earlier ART eligibility expansions, there were large differ-
ences in the proportion initiating ART among those with CD4 counts above the treatment eli-
gibility threshold and those with CD4 counts below the threshold. For example, after eligibility
expansion to CD4� 500 cells/μl, there was a 17.6-pp difference in rapid ART initiation
between patients enrolling with CD4 counts of 451 to 500 cells/μl and those with CD4 counts
of 501 to 550 cells/μl (58.9% versus 41.3%; medium blue points in Fig 1). In contrast, under
treat all, there was little difference in rapid ART initiation across CD4 count levels, as indicated
by the lack of any inflection point (dark blue points in Fig 1).
Effect of treat all adoption on rapid ART initiation (regression
discontinuity analysis)
In 4 of the 6 countries, there was a statistically significant increase in rapid ART initiation
immediately following national adoption of treat all. The effect was greatest in Rwanda, with a
34.5-pp increase (95% CI 27.2 to 41.7): 78.9% of patients enrolling immediately after treat all
adoption initiated ART rapidly, compared with 44.4% of patients enrolling immediately before
the policy change (a 77.7% relative increase). Increases were more moderate in Kenya
Treat all policies and rapid treatment initiation
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Table 1. Baseline characteristics of patients enrolling in all 4 ART eligibility periods between 2004 and 2018 (N = 814,603).
Characteristic Overall Period 1
(CD4� 200/250 cells/μl)
Period 2
(CD4� 350 cells/μl)
Period 3
(CD4� 500 cells/μl)
Period 4
(treat all)
Total N 814,603 389,416 216,832 169,822 38,533
Burundi
Date of guideline expansion October 2010 August 2014 September 2016
N 11,176 5,883 3,031 1,233 1,029
Median age (IQR) (years) 36 (28–44) 36 (29–45) 35 (28–44) 36 (27–45) 36 (27–45)
Percent female 63.8 65.7 61.6 63.3 59.7
Percent with enrollment CD4 count 19.1 13.3 33.6 16.0 13.4
Median enrollment CD4 count (IQR) (cells/μl) 302 (169–495) 257 (151–417) 323 (174–521) 347 (178–531) 432 (250–653)
Kenya
Date of guideline expansion November 2011 June 2014 July 2016
N 179,941 114,230 32,830 22,645 10,236
Median age (IQR) (years) 34 (27–41) 34 (28–42) 32 (26–40) 32 (26–41) 34 (28–43)
Percent female 66.5 67.6 66.0 64.6 59.7
Percent with enrollment CD4 count 73.5 81.4 69.7 57.3 32.6
Median enrollment CD4 count (IQR) (cells/μl) 242 (98–435) 228 (92–417) 267 (107–461) 302 (135–498) 272 (114–479)
Malawi
Date of guideline expansion July 2011 April 2014 July� 2016
N 84,558 37,215 24,803 18,881 3,659
Median age (IQR) (years) 32 (27–39) 33 (27–40) 32 (26–38) 32 (26–39) 32 (26–39)
Percent female 63.5 61.9 66.3 63.3 61.6
Percent with enrollment CD4 count 34.7 42.4 30.9 30.8 3.0
Median enrollment CD4 count (IQR) (cells/μl) 221 (115–352) 187 (93–295) 261 (146–391) 283 (156–431) 244 (154–411)
Rwanda
Date of guideline expansion August 2007 August 2011 July 2016
N 17,396 5,477 5,581 5,048 1,290
Median age (IQR) (years) 32 (26–39) 34 (28–40) 31 (26–38) 31 (25–38) 32 (26–39)
Percent female 61.5 64.8 59.3 61.7 56.7
Percent with enrollment CD4 count 75.3 67.2 79.8 79.9 72.2
Median enrollment CD4 count (IQR) (cells/μl) 350 (189–548) 278 (140–489) 364.5 (213–558) 384.5 (223–574) 391 (215–582)
Uganda
Date of guideline expansion June 2011 December 2013 November 2016
N 96,286 53,028 20,956 17,909 4,393
Median age (IQR) (years) 32 (26–39) 33 (27–40) 30 (25–38) 30 (24–37) 30 (24–37)
Percent female 62.8 64.2 61.7 60.5 61.3
Percent with enrollment CD4 count 72.5 69.7 79.3 78.7 49.3
Median enrollment CD4 count (IQR) (cells/μl) 278 (122–477) 236 (95–438) 315 (155–502) 337 (170–516) 334 (150–529)
Zambia
Date of guideline expansion June 2010 December 2013 December 2016
N 425,246 173,583 129,631 104,106 17,926
Median age (IQR) (years) 33 (28–40) 33 (28–40) 33 (27–40) 33 (27–40) 32 (26–39)
Percent female 62.0 62.9 61.6 61.3 60.8
Percent with enrollment CD4 count 67.2 79.8 66.7 52.4 34.0
Median enrollment CD4 count (IQR) (cells/μl) 226 (111–385) 195 (94–342) 253 (129–410) 270 (135–436) 289 (149–469)
�Adjusted based on documented policy rollout delays (see Methods).
https://doi.org/10.1371/journal.pmed.1002822.t001
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(25.7 pp, 95% CI 21.8 to 29.5), Burundi (17.7 pp, 95% CI 6.5 to 28.9), and Malawi (12.5 pp,
95% CI 7.5 to 17.5). No statistically significant discontinuity effect was observed at the treat all
threshold in Uganda (−4.2 pp, 95% CI −9.0 to 0.7) or Zambia (0.4 pp, 95% CI −2.9 to 3.8). The
Table 2. Proportion of patients enrolling in HIV care under treat all and initiating ART on the day of enrollment, within 7 days, and within 30 days (“rapid ART
initiation”).
Sample Number of enrollees under treat all Period of enrollment Proportion of patients initiating ART
On the day of enrollment Within 7 days of enrollment Within 30 days of enrollment
Overall 38,533 May 2016–Jul 2018 59.2% 67.1% 81.6%
By country
Burundi 1,029 Sep 2016–Jul 2018 32.7% 55.4% 77.9%
Kenya 10,236 Jul 2016–Jan 2018 63.6% 67.1% 83.1%
Malawi 3,659 Jul 2016–Nov 2016 69.5% 82.5% 88.9%
Rwanda 1,290 Jul 2016–Dec 2017 25.7% 56.7% 86.9%
Uganda 4,393 Nov 2016–Jan 2018 66.3% 71.7% 81.2%
Zambia 17,926 Dec 2016–Aug 2017 56.7% 64.2% 79.1%
https://doi.org/10.1371/journal.pmed.1002822.t002
Fig 1. Rapid ART initiation (within 30 days of enrollment) across ART eligibility periods and enrollment CD4 counts (cells/μl).
https://doi.org/10.1371/journal.pmed.1002822.g001
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pooled estimate of effect at the treat all threshold was 14.2 pp (95% CI 2.2 to 26.2) (Table 3; Fig
2).
Results of sensitivity analyses using other bandwidths were consistent with the findings
based on the data-driven Imbens–Kalyanaraman bandwidth (S2 Table).
Trends in rapid ART initiation before and after treat all adoption
After treat all adoption, the rate of change in rapid ART initiation increased most in Malawi
(from 0.1 pp per month before treat all adoption to 2.8 pp per month afterwards), Zambia
(from 0.2 pp to 2.6 pp), and Uganda (from 0.4 pp to 2.2 pp; all p< 0.001). A decrease in the
rate was observed in Kenya (from 0.6 pp to 0.3 pp per month; p = 0.006).
Correlates of failure to initiate ART rapidly under treat all
In post hoc analyses employing multivariable models restricted to patients enrolling under
treat all, persons ages 16–24 years had an 18% greater risk of not starting ART rapidly, com-
pared with those�25 years old (adjusted risk ratio [aRR] = 1.18, 95% CI 1.12 to 1.24), and
men had a 12% higher risk than women (aRR = 1.12, 95% CI 1.07 to 1.17). There was an
inverse relationship between time elapsed since treat all adoption and failure to initiate ART
rapidly: At 12 months after treat all adoption, new enrollees had 47% lower risk of not starting
ART rapidly compared to those who enrolled in the first 3 months after the policy was adopted
(aRR = 0.53, 95% CI 0.48 to 0.58) (Table 4).
Discussion
We found that adoption of treat all policies at the national level in 6 African countries was fol-
lowed by appreciable increases in the proportion of patients initiating ART rapidly (within 30
Table 3. Effect of enrollment under treat all on rapid ART initiation (within 30 days of enrollment), by country and pooled, and slopes before and after treat all
adoption.
Measure Pooled Rwanda Kenya Burundi Malawi Zambia Uganda
Risk difference at the treat all adoption threshold� 14.2 34.5 25.7 17.7 12.5 0.4 −4.2
95% CI (2.2,
26.2)
(27.2,
41.7)
(21.8,
29.5)
(6.5,
28.9)
(7.5,
17.5)
(−2.9,
3.8)
(−9.0,
0.7)
p-Value 0.020 <0.001 <0.001 0.002 <0.001 0.804 0.090
Imbens–Kalyanaraman bandwidth, days 405 158 376 97 79 205
N within bandwidth 2,189 8,052 1,163 5,020 12,762 5,371
Predicted outcomes at the treat all threshold�
Enrollment just before treat all adoption 44.4% 55.0% 55.7% 68.6% 62.4% 70.6%
Enrollment just after treat all adoption 78.9% 80.7% 73.4% 81.1% 62.8% 66.4%
Relative change after treat all adoption 77.7% 46.7% 31.8% 18.2% 0.6% −5.9%
Slopes before and after treat all adoption��
Percentage point change in rapid ART initiation per month before treat all
adoption
0.4 0.6 0.6 0.1 0.2 0.4
Percentage point change in rapid ART initiation per month after treat all
adoption
0.8 0.3 0.7 2.8 2.6 2.2
p-Value for difference of slopes 0.105 0.006 0.619 <0.001 <0.001 <0.001
�Risk difference and predicted outcomes at the treat all threshold are from regression discontinuity analysis. Effects are calculated at the modified guideline expansion
threshold of 31 days before versus 1 day after treat all adoption.
��Slope comparison is from separate linear regression models comparing the period before treat all adoption (starting 90 days after ART eligibility expansion to
CD4� 500 cells/μl) and after adoption.
https://doi.org/10.1371/journal.pmed.1002822.t003
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days of enrollment) in diverse, largely public-sector service delivery settings. Regression dis-
continuity analysis found marked increases in rapid ART initiation in most of the countries
immediately after the national adoption of treat all. Our study provides evidence, outside of a
controlled research environment, of a causal effect of national adoption of the treat all policy
Fig 2. Rapid ART initiation (within 30 days of enrollment) by ART eligibility period and country, 2007–2018. Labels include effect sizes (percentage point
[pp] change in the proportion of patients rapidly initiating ART) and 95% confidence intervals from the regression discontinuity analysis across the treat all
adoption date threshold. Dotted lines on either side of the treat all date represent the width of the Imbens–Kalyanaraman bandwidth used in the regression
discontinuity analysis. In order to comprehensively present observed trends, the graphs include the 30-day period preceding treat all adoption, which was
excluded from regression discontinuity analysis (Table 3). The first 2 ART eligibility expansions (to CD4� 350 and� 500 cells/μl) were not included in the
regression discontinuity analysis, and data for the CD4� 350 cells/μl and CD4� 500 cells/μl eligibility periods are shown only for context. The plots include
first degree local polynomial smooth curves intended for illustrative purposes and are distinct from the regression discontinuity models described in the
Methods, from which effect estimates were derived.
�Adjusted based on documented policy rollout delays (see Methods).
https://doi.org/10.1371/journal.pmed.1002822.g002
Table 4. Correlates of failure to initiate ART rapidly (within 30 days of enrollment) under treat all (N = 38,533).
Characteristic N RR (95% CI) p-Value aRR (95% CI) p-Value
Age
16–24 years 7,259 1.15 (1.10, 1.21) <0.001 1.18 (1.12–1.24) <0.001
�25 years 31,274 Ref Ref
Sex
Male 15,220 1.08 (1.04, 1.13) <0.001 1.12 (1.07–1.17) <0.001
Female 23,313 Ref Ref
Time between treat all adoption and enrollment
0 to <3 months 14,075 Ref <0.001 Ref <0.001
3 to <6 months 12,035 0.74 (0.70, 0.77) 0.71 (0.68–0.75)
6 to <12 months 8,737 0.67 (0.63, 0.71) 0.63 (0.59–0.66)
�12 months 3,686 0.57 (0.53, 0.63) 0.53 (0.48–0.58)
Model also adjusted for country.
aRR, adjusted risk ratio; RR, risk ratio.
https://doi.org/10.1371/journal.pmed.1002822.t004
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on sustained improvements in rapid ART initiation following HIV care enrollment, with no
apparent negative effects on ART initiation for those eligible under prior treatment guidelines.
In half of the countries in the analysis, immediate relative increases in rapid ART initiation
at the regression discontinuity threshold (ranging from 31.8% to 77.7% in Burundi, Kenya,
and Rwanda) were larger than the 26.7% increase in the number of ART initiators predicted
for a 1-year period after treat all adoption by a recent empirical modeling study for South
Africa [26], and similar to those observed in a recent trial in Eswatini [12] and a recent analysis
of ART uptake in Rwanda following national adoption of treat all [27].
Improvements were sustained or further amplified following national adoption of treat all.
In Malawi, Uganda, and Zambia, the rate of change in rapid ART initiation increased sharply
in the months following the date of treat all adoption, suggesting that implementation of
expanded treatment eligibility guidelines may have been phased in or delayed. This was partic-
ularly true in Uganda and Zambia, where no effect was observed at the threshold. Lack of an
immediate effect may also suggest that there were few newly eligible patients at the time when
treat all was adopted, or it may reflect regression to the mean, given already-high levels of
rapid ART initiation in the months leading up to eligibility expansion.
Previous studies have reported lower rates of ART initiation among men [9,28] and young
adults [6,29], compared to women and older adults. Similarly, while rapid ART initiation rates
improved for both groups following the adoption of treat all, our analysis found that men and
young adults remained at greater risk of not initiating ART rapidly. While we found that the
risk of failing to rapidly initiate ART decreased markedly with time following national adop-
tion of treat all, as more follow-up data become available, future research should assess
whether age and sex disparities in ART initiation diminish over time.
Overall, there were no appreciable differences in rates of rapid ART initiation across differ-
ent enrollment CD4 counts. If observed, such differences would have suggested that the sickest
patients were being “crowded out” by patients with less advanced disease under treat all. While
these findings are consistent with research assessing the impacts of prior ART eligibility expan-
sions [6,7,30], there may be variations at the country or site level that we were unable to assess
in stratified analyses, largely because substantially fewer patients under treat all have enroll-
ment CD4 counts measured before ART initiation.
A major strength of our study is the use of a regression discontinuity design and service
delivery data that reflect diverse real-world implementation settings in sub-Saharan Africa,
which provide support for a causal interpretation of the association between expanded ART
eligibility under treat all and increases in rapid ART uptake [20]. The use of data-driven
Imbens–Kalyanaraman optimal bandwidths and sensitivity analyses with 3 other constant
bandwidths enabled us to generate robust effect estimates with minimal risk of researcher bias
[22].
However, a limitation of our study is incomplete data on potential ART eligibility criteria,
such as clinical status (including TB coinfection) and pregnancy, as well as enrollment CD4
count. Such data would have better elucidated the actual ART eligibility status of patients
enrolling before treat all. These gaps precluded the implementation of a “fuzzy” regression dis-
continuity design, which would better reflect the probabilistic distribution of ART eligibility in
the pre-treat-all sample [18]. Similarly, we were unable to assess rapid ART initiation specifi-
cally among patients previously eligible for ART, which could have provided insights into bar-
riers to rapid ART initiation in the pre-treat-all era (e.g., capacity constraints and/or delays in
eligibility ascertainment versus adherence to policy at the time). In addition, the limited avail-
ability of data on patient characteristics other than age, sex, and enrollment CD4 count
restricted our ability to assess whether patients on each side of the regression discontinuity
threshold were similar with respect to other pre-treatment covariates.
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Another limitation is that the exact date of treat all policy adoption at the site level is
unknown for many IeDEA sites, and delays in site-level implementation of expanded treat-
ment eligibility guidelines likely varied within and across countries. Such potential non-differ-
ential exposure misclassification would be expected to attenuate observed effects and may have
contributed to the observed results in Uganda and Zambia (i.e., no increase in rapid ART initi-
ation at the regression discontinuity threshold, but increases in ART initiation rates with
increasing time after national adoption of treat all). At the same time, if facilities contributing
data to an international collaboration such as IeDEA have a greater capacity to rapidly imple-
ment policy changes, the threshold effects we found may overestimate the effects of the adop-
tion of treat all in the respective countries.
These findings are nonetheless important, given previous research showing that loss to care
between diagnosis and ART initiation is the most common “breakpoint” in the HIV care con-
tinuum [31], as well as recent evidence of improved retention in care among those who are
immediately eligible for ART [4,11,19]. As more data on HIV care under treat all become
available, research should assess longer-term patient outcomes, including rate of and time to
viral load suppression among patients who immediately initiate ART. Recent findings from a
trial in Eswatini have reported large improvements in viral load suppression under treat all
[11]; however, additional analyses utilizing real-world service delivery data from diverse coun-
try contexts and quasi-experimental designs will be important for deriving generalizable effect
estimates of the individual- and population-level benefits of treat all policies. Country-specific
analyses incorporating multiple change points for treatment eligibility expansions could pro-
vide additional insight into the relative impacts of distinct policies over time in diverse con-
texts. Further research into health system constraints, demand-side barriers, and underserved
populations is also critical for understanding the drivers of between-country differences in the
effect of treat all policies on rapid ART initiation. Equally important is implementation
research to identify effective strategies for increasing the uptake of HIV testing and linkage to
care [26,32], as well as for optimizing patient outcomes along the HIV care cascade under treat
all [33]. Finally, as more follow-up data under treat all become available, questions around
retention and viral suppression, as well as treatment failure and subsequent regimen switches,
will be important to examine.
In conclusion, our study demonstrates a strong and sustained effect of national-level adop-
tion of treat all policies on rapid ART initiation in diverse service delivery settings across 6
sub-Saharan African countries. This provides further evidence of treat all being a key strategy
towards the achievement of UNAIDS 90-90-90 targets.
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